These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30986790)

  • 21. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
    Park J; Archuleta S; Oh MH; Shek LP; Wang H; Bonaparte M; Frago C; Bouckenooghe A; Jantet-Blaudez F; Begue S; Gimenez-Fourage S; Pagnon A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2107-2116. PubMed ID: 33626291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
    Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
    Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.
    Velumani S; Toh YX; Balasingam S; Archuleta S; Leo YS; Gan VC; Thein TL; Wilder-Smith A; Fink K
    Hum Vaccin Immunother; 2016 May; 12(5):1265-73. PubMed ID: 26889737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
    Glass A; Polhemus M; Wang D; Jarman RG; Thomas SJ; Friberg H; Currier JR; Bonaparte M; De La Barra R; Princiotta MF; Abbott M; Cuzzo B; Machabert T; Sridhar S; Endy TP
    J Infect Dis; 2020 Mar; 221(7):1057-1069. PubMed ID: 31755526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
    Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
    Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
    Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
    J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
    J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
    Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
    Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.
    Santos J; Montellano ME; Solante R; Perreras N; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Pediatr Infect Dis J; 2021 Sep; 40(9):856-863. PubMed ID: 34117198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
    Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
    J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.